Suggested remit: To appraise the clinical and cost effectiveness of tabelecleucel within its marketing authorisation for previously treated post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus.
Status In progress
Technology type Medicine
Decision Selected
Process STA 2022
ID number 1203

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 09 June 2022 - 07 July 2022
Scoping workshop 01 August 2022 (14:00)

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 April 2017 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual